Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

International, Multicenter, Double-blind, Randomized, Comparative Study of Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma

NCT06320353 is registered in ClinicalTrials.gov with R-Pharm as lead sponsor.

NCT NCT06320353
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06320353 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
International, Multicenter, Double-blind, Randomized, Comparative Study of Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma
Lead sponsor
R-Pharm
Phase
Phase 3
Overall status
Completed
Start date
September 27, 2023
Completion date
March 2, 2026
Enrollment
266 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

skin melanoma